Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman · Nature reviews. Cancer · 2009
Cited by 2,438 works. doi:10.1038/nrc2664
Authors
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- SH2 domains recognize specific phosphopeptide sequences
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
- Phosphatidylinositol-3-OH kinase direct target of Ras